Most notably, this increased tumor uptake was accompanied by murine kidney uptake that was 44 times higher with PSMA-TO-1 than with PSMA-617 24 h after administration, which translates to a 26-fold greater kidney dose in mice. The gene discussed is FOLH1; the disease is neoplasm.